Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Caprion's E.Coli Treatment Shows Promise | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Caprion’s E.Coli Treatment Shows Promise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Caprion Pharmaceuticals completed Phase I studies for Shigamabs, its product for the treatment of Shigatoxin-producing E. coli infections (STEC), including the O157:H7 strain involved in the current U.S. outbreak. The severe clinical symptoms such as hemorrhagic colitis, thrombocytopenia, hemolytic anemia and hemolytic uremic syndrome in as many as 60% of all infected patients, are potentially lethal in the most severe cases. Serious complications are most frequent in young children and the elderly. There are no treatments currently available for STEC infections.

The safety and tolerability of the company’s anti-toxin antibodies were evaluated in 40 healthy adult volunteers. Shigamabs were shown to be safe and well tolerated in three studies conducted over the last four years at major medical centers in the U.S. and Canada.

Caprion is planning a Shigamabs trial in the EU and North America in 2007 pending final regulatory review.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters